Sat Kartar Life’s record shows a company in transition: a clean audit trail, zero promoter pledges, and a 23% revenue jump sit alongside two years of negative free cash flow and a receivables book growing twice as fast as sales. The pivot from Ayurvedic products into hospital operations is being funded with IPO proceeds, while the group added four subsidiaries in a single year, including a US entity for which RBI approval was pending in March 2026.
Key findings
- Operating cash flow is disconnected from reported profit
Major- Profit after tax rose to ₹17.10 crore in FY26, yet operating cash flow was just ₹0.48 crore, a cash conversion ratio of 0.03 times. In FY25, PAT was ₹9.82 crore against a negative CFO of ₹5.07 crore. Free cash flow was negative for both years, ₹-6.93 crore in FY26 and ₹-9.88 crore in FY25, while the company paid ₹1 crore in dividends in FY26. Management attributed the gap to working capital tied up in a factory build, the Plantomed acquisition, and inventory investment during a post-IPO transition phase. - Receivables are growing twice as fast as revenue
Major- Days Sales Outstanding rose 96% from FY25 to FY26, with the receivables-to-revenue growth ratio reaching 1.96. Revenue from operations grew 23% to 201 crore, while receivables climbed to 14.47 crore. Management’s FY28 revenue target of ₹500 crore rests on a monthly run-rate of ₹30-35 crore in FY27, yet the Delhi hospital had not crossed 10% occupancy after 40 days of operation and was generating ₹50,000 per day against a break-even of ₹1,00,000 per day. - RBI approval for US subsidiary was pending in March 2026
Major- Management stated in March 2026 that the US entity Plantomed (Sat Kartar USA INC) was “already operational with a bank account” but RBI approval for direct overseas investment was pending, calling it “not a subsidiary yet.” On 29 June 2026, the company announced commencement of commercial operations in the USA through that same wholly owned subsidiary. Separately, Sat Kartar Ocean Private Limited was incorporated as a marketing conduit to obtain advertising discounts from Google and Facebook, with no operations started as of March 2026. - ₹2.05 crore in interest-free loans went to subsidiaries with no repayment terms
Major- The company granted unsecured, interest-free loans of ₹92.21 lakh to Plantomed Nutraceuticals and ₹1.13 crore to Ajooni Life Sciences, repayable on demand with no stipulated repayment or interest schedule. The auditor’s CARO report, a regulatory annexure on company financial practices, confirms these loans carry no specified terms or period of repayment. The Board also approved the acquisition of Sat Kartar USA Inc, a nil-turnover entity whose director was a relative of the promoter, on 15 October 2025. - Promoters seek remuneration above statutory limits while expanding ESOP schemes
Minor- The Board seeks a special resolution to pay managerial remuneration for FY2026-27 that may exceed limits under Section 197 of the Companies Act, 2013, repeating a similar resolution sought for FY2025-26. Two employee stock option schemes were approved within four months, one on 4 December 2025 and another on 22 March 2026, with the latter permitting a trust route and loans to purchase own shares. Promoter shareholding stands at 63.62% with zero pledge.
What to watch
- RBI approval for US subsidiary. As of the March 2026 management call, RBI approval for direct overseas investment in Sat Kartar USA INC was pending.
- Delhi hospital break-even. Management stated in March 2026 that the Delhi hospital was generating ₹50,000 per day against a break-even of ₹1,00,000 per day.
- Hospital funding sufficiency. Management stated in the Q4 FY26 call that the first hospital required a CAPEX of 7-8 lakhs per bed, with a facility becoming operational at 3-4 lakhs per bed, and that scaling to 1,000 beds would require approximately ₹40 crore.
- FY28 revenue target. The ₹500 crore target rests on a monthly run-rate of ₹30-35 crore in FY27, as stated on the Q4 FY26 call.
Bottom line: This is a disclosed record with a clean audit opinion and zero promoter pledges, but the cash engine is not yet self-sustaining. The risk sits in execution: a hospital ramp that is still below break-even occupancy after 40 days of operation, a receivables cycle that is lengthening as the government customer mix grows, and a group structure that added four entities in a year, one of which commenced US operations while RBI approval was pending as of March 2026. Watch the Delhi hospital’s occupancy and empanelment milestones, and whether the US subsidiary secures RBI approval.